BAT as a therapeutic for the metabolic and cardiac dysfunction with senescence.

BAT 作为治疗衰老代谢和心脏功能障碍的药物。

基本信息

批准号：
10557231
负责人：
Paul Martin Coen
金额：
$ 57.96万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-05-15 至 2025-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10557231
关键词：
Ablation Acceleration Acute Address Adult Affect Age Age Years Aging Area Body Composition Body mass index Brown Fat Cardiovascular Diseases Cardiovascular Physiology Cardiovascular system Chemicals Chronic Collaborations Data Development Disease Echocardiography Educational Intervention Elderly Endocrine Energy Metabolism Excision Exercise Fatty Acids Genetic Glucose Goals Health Healthcare Heart Homeostasis Human Impairment Injections Left Link Lipids Metabolic Metabolic Diseases Metabolic dysfunction Metabolism Mitochondria Mus Myocardial dysfunction Non-Insulin-Dependent Diabetes Mellitus Obesity Osmosis Performance Peripheral Phenotype Physiologic intraventricular pressure Plasma Play Population Process Pump Research Proposals Risk Factors Rodent Role Signal Transduction Testing Therapeutic Tissue Transplantation Tissues Transplantation VO2max age effect aged aging population cardiovascular health combat comorbidity disorder risk exercise training experimental study fatty acid metabolism glucose metabolism glucose uptake heart function improved in vivo innovation insulin sensitivity mortality novel novel therapeutic intervention oxidation pre-clinical pressure respiratory response sedentary senescence therapeutic target tool uptake young adult

项目摘要

PROJECT SUMMARY/ABSTRACT The US population is rapidly aging. It is projected that by 2030, more than 20% of the population will be over 65 years of age1. Aging is accompanied by increased metabolic and cardiovascular disease. An important tissue to combat metabolic disease and influence heart function is brown adipose tissue (BAT). Brown adipose tissue (BAT) is a thermogenic tissue that has a high capacity for both glucose and lipid oxidation, making BAT a potential target to decrease plasma glucose and lipids and to protect against obesity and it's co- morbidities, including type 2 diabetes and cardiovascular disease (CVD). Increasing the amount of BAT by transplantation improves metabolic health, reduces adiposity, and increases glucose uptake into the heart. BAT has great potential as a therapeutic target to combat both metabolic and cardiovascular disease, but BAT decreases with age. Thus, we hypothesized that increasing BAT could be a potential therapeutic to improve the metabolic and cardiovascular impairments that occur with aging. Our preliminary data demonstrate that transplantation of BAT into an aged mouse (18 months) improves metabolic and cardiovascular health. We have also generated exciting data showing that exercise increases the signaling lipid 12,13-diHOME from BAT in humans. 12,13-diHOME is decreased with age in both humans and mice, while exercise in an elderly population restores 12,13-diHOME to concentrations similar to young adult subjects. Injection of this lipid into mice has a direct effect on the heart, increasing left ventricular pressure development. Taken together, our exciting preliminary data show that 1) transplantation of BAT improves metabolic and cardiovascular health in an aged mouse; 2) exercise-training increases the signaling lipid 12,13-diHOME; 3) concentrations of 12,13- diHOME are decreased with age in humans and mice; and 4) injection of 12,13-diHOME in mice directly affects heart function. Here, we will test the novel paradigm that BAT exerts endocrine effects that improves metabolic health and cardiac function in senescence with three specific aims: 1) Determine the role of BAT on age-induced impairments in metabolism and insulin sensitivity; 2) Determine the role of BAT on the age- induced impairments in cardiac function; and 3) Determine if BAT mass and endocrine function is linked with metabolism or cardiac function in older adults. This project will establish if increasing BAT, and specifically the lipid 12,13-diHOME, negates the metabolic and cardiovascular impairments that occur with senescence in rodents and humans. The proposed studies have the potential to elucidate a novel role, and potential therapeutic approach, for BAT to negate the detrimental effects of aging. .

项目摘要/摘要美国人口正在迅速衰老。预计到2030年，超过20％的人口将结束 65岁。衰老伴随着代谢和心血管疾病的增加。一个重要的棕色脂肪组织（BAT）是对抗代谢疾病和影响心脏功能的组织。棕色的脂肪组织（BAT）是一种热组织，具有葡萄糖和脂质氧化的高容量，使BAT成为减少血浆葡萄糖和脂质并预防肥胖症的潜在目标病态，包括2型糖尿病和心血管疾病（CVD）。增加蝙蝠的量移植可改善代谢健康，降低肥胖，并增加葡萄糖的摄取。 BAT作为对抗代谢和心血管疾病的治疗靶标具有很大的潜力，但BAT 随着年龄的增长而减小。因此，我们假设增加的蝙蝠可能是改善的潜在治疗方法衰老会出现的代谢和心血管障碍。我们的初步数据表明将蝙蝠移植到老鼠（18个月）中可改善代谢和心血管健康。我们还产生了令人兴奋的数据，表明运动增加了蝙蝠的信号传导脂质12,13-dihome 在人类中。在人类和小鼠中，随着年龄的增长，12,13-dihome在老年人中运动时都会减少人口可恢复12,13个与年轻受试者相似的浓度。注射此脂质小鼠对心脏有直接的影响，增加了左心压发展。总的来说，我们的令人兴奋的初步数据表明，1）蝙蝠的移植可改善代谢和心血管健康老鼠; 2）运动训练增加信号脂质12,13-dihome； 3）12,13-的浓度人类和小鼠的年龄随着年龄的增长而减少。 4）直接在小鼠中注射12,13-dihome 影响心脏功能。在这里，我们将测试蝙蝠发挥内分泌效应的新颖范例，以改善代谢健康和衰老中的心脏功能具有三个特定目的：1）确定蝙蝠在年龄引起的新陈代谢和胰岛素敏感性的损害； 2）确定蝙蝠对年龄的作用 - 诱导心脏功能受损； 3）确定蝙蝠质量和内分泌功能是否与老年人的代谢或心脏功能。该项目将确定是否增加了蝙蝠，特别是脂质12,13-dihome，否定衰老中发生的代谢和心血管障碍啮齿动物和人类。拟议的研究有可能阐明新作用，并有潜力治疗方法，使BAT消除衰老的有害影响。。